产品名称 | NebuSelect™ Recombinant Human IL-20RA, hFc-tag |
---|---|
目录号 | NBL-242487 |
别名 | IL-20RA; IL-20R-alpha; IL-20RA; CRF2-8; IL-20R1; ZcytoR7; FLJ40993 |
外观 | see COA |
分子量 | Val30-Lys250 |
CAS | N/A |
溶解度 | Water Soluble |
存储条件 | Short term 4℃; Long term -20℃. |
保存时间 | 2 years |
备注1 | Q9UHF4-1 |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBL-242487-100ug | 100ug | Inquire | Inquire | |
NBL-242487-1mg | 1mg | Inquire | Inquire | |
NBL-242487-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Human IL-20RA, hFc-tag
Catalog#:
NBL-242487
Description:
NebuSelect™ Recombinant Human IL-20RA, hFc-tag(Cat#NBL-242487) is expressed in HEK293 with hFc tag at the C-Terminus.It contains Val30-Lys250.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 52 kDa. Due to glycosylation, the protein migrates to 65-70 kDa based on Bis-Tris PAGE result.
Target Name:
IL-20RA; IL-20R-alpha; IL-20RA; CRF2-8; IL-20R1; ZcytoR7; FLJ40993
Target Information:
IL-20RA was highly expressed in the tumor tissue of CRC and related to the advanced stage.IL-20RA was involved in regulating oncogenic and immune pathways and affecting the expression of genes related to cell proliferation and immune evasion in CRC.Super-enhancer inhibition by JQ-1 or iBET-151 suppressed the growth of tumor cells and inhibited the expression of IL-20RA.
Amino Acid Sequence:
Val30-Lys250
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.